Skip to content

The END Perioperative Smoking Pilot Study

A Pilot Randomized Controlled Clinical Trial - Electronic Nicotine Delivery Device (E-cigarette) for Perioperative Smoking Cessation in Veterans

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02482233
Enrollment
30
Registered
2015-06-26
Start date
2015-08-31
Completion date
2016-09-30
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Addiction, Smoking, Surgery

Keywords

electronic cigarette, nicotine replacement therapy, smoking cessation, perioperative

Brief summary

The purpose of this pilot randomized trial is to determine the feasibility of e-cigarettes and telephone counselling (compared to transdermal nicotine replacement and telephone counselling) as a harm-reduction tool that may lead to increased smoking cessation in the perioperative setting in smokers presenting for elective surgery at the San Francisco Veterans Affairs Medical Center. Secondary outcomes include acceptability of e-cigarettes over transdermal nicotine replacement, length-of-stay in the post-anesthesia care unit, hospital length-of-stay, postoperative complications within the first 30-days, and smoking status 8-weeks after randomization. This pilot study is designed to provide the preliminary data necessary to plan and fund a larger-scale randomized clinical trial that will assess the utility of e-cigarettes in achieving smoking cessation perioperatively. Our ultimate goal is to add to the limited existing data on the safety and efficacy of e-cigarette use in smoking cessation, specifically in the perioperative setting where the risks of continued smoking are great and the motivation to stop is high.

Detailed description

It is well-known that smokers suffer more complications and higher risk of mortality after surgery than non-smokers. Despite this knowledge, it is unclear what clinicians can do to minimize this risk. Surgery represents a 'teachable moment' that might encourage smokers to engage in permanent cessation. Several small trials have shown that smoking cessation interventions can increase smoking cessation and reduce postoperative complications, particularly wound-healing complications, which can have an absolute risk reduction of up to 25%. Smoking cessation initiated in the perioperative period can also promote long-term smoking cessation. Despite the benefits of comprehensive smoking cessation interventions including nicotine replacement therapy, current standard of care at the SFVAMC does not routinely include specific preoperative smoking cessation pharmacotherapy or counselling. Although there is an urgent need for more data, e-cigarettes have been proposed as an alternative to nicotine replacement therapy that are at least as effective for smoking cessation, and may be more acceptable to some patients. The main hypothesis of this pilot study is that the use of e-cigarettes and telephone counselling, compared to telephone counselling and transdermal nicotine replacement, in the perioperative period results in increased smoking cessation on the day of surgery and at 8-weeks after randomization in smokers presenting for elective surgery. As secondary hypotheses, the study will also assess the acceptability of e-cigarettes versus nicotine patches, postoperative complications within the first 30-days, length-of-stay in the PACU and hospital length-of-stay. The investigators will examine the above hypotheses through the following aims: Aim 1) To determine how e-cigarettes plus counselling compare to transdermal nicotine replacement plus counselling for the achievement of smoking cessation, when introduced prior to elective surgery in veterans. The investigators plan to carry-out a pilot randomized controlled trial with parallel design comparing e-cigarettes and telephone counselling with transdermal nicotine replacement and telephone counselling. Our primary outcome is smoking cessation on the day of surgery, as confirmed biochemically by exhaled carbon monoxide. Smoking reduction (self-reported cigarettes per day) of 50% or more and bedside spirometry readings will be assessed as secondary outcomes. Aim 2) To determine the acceptability of e-cigarettes amongst veterans as an aid for smoking cessation and to determine the feasibility of recruitment, randomization, and follow-up procedures in preparation for large-scale trial. Through implementation of this pilot trial, the investigators will determine the feasibility and acceptability of e-cigarettes for smoking cessation perioperatively in the veteran population and obtain the preliminary data necessary to run a larger trial on the effectiveness of e-cigarettes as a perioperative smoking cessation aid. Aim 3) To determine the safety of e-cigarettes as a harm reduction strategy to achieve short-term perioperative smoking cessation. The investigators plan to improve the overall knowledge of the safety of short-term e-cigarettes use through careful surveillance for adverse events and side effects. Aim 4) To determine if e-cigarette use preoperatively is associated with a lower risk of complications postoperatively. The investigators plan to measure the following secondary outcomes: postoperative complications and mortality within the first 30 days, post-anesthesia care unit (PACU) length-of-stay, and hospital length-of-stay. This will help us understand if e-cigarettes have the potential to be used for harm-reduction perioperatively.

Interventions

BEHAVIORALENDD (NJOY)

As described above.

DRUGNRT (NicoDerm CQ)

As described above.

BEHAVIORALtelephone counseling

Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.

BEHAVIORALbrief advice

Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.

BEHAVIORALbrochure

A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery. Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure\_%20For%20Posting.pdf

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adults (age \>18) * any gender * scheduled to undergo elective surgery at the San Francisco Veterans Affairs Medical Center (SFVAMC) * daily smoker, based on self-report of at least 2 cigarettes/day and having smoked in the last 7 days * presenting to the anesthesia preoperative (APO) clinic at least 3 days preoperatively

Exclusion criteria

* emergency surgery (booked \<24 hours preoperatively) * consumers of non-cigarette forms of tobacco only (pipe, smokeless tobacco) or marijuana only * already enrolled in a smoking cessation trial * current smoking cessation pharmacotherapy * daily user of e-cigarettes * previous adverse reaction to e-cigarette or transdermal nicotine * poor proficiency of English language¸as indicated by need for an interpreter (including family members) at the preadmission visit * lacking capacity for consent (e.g. due to mental illness or dementia), as indicated by consent for surgery and other medical procedures being obtained from a substitute decision maker * pregnant or breastfeeding * unstable cardiac condition (unstable angina, unstable arrhythmia)

Design outcomes

Primary

MeasureTime frameDescription
Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)day of surgery (expected average around 1-2 weeks after enrollment/randomization)Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide \<10ppm. Time Frame depends on date of preadmission clinic visit

Secondary

MeasureTime frameDescription
Report of How Helpful the Product Was for Quitting8-weeks7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
How Satisfied the Patient Was With the Product (E-cigarette or Patch)8-weeks7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others8-weeks7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)8-weeksby self-report and confirmed by exhaled CO\<10ppm - confirmed abstinent
Smoking Reductionon day of surgery and 8-weeks after randomization50% or less regular cigarette use compared to baseline as determined by asking participants to self-report daily cigarette use in cigarettes per day at each time point.
Number of Participants With Dual Useon day of surgery and 8-weeks after randomizationuse of both regular and e-cigarettes concurrently
Frequency of Use of Product - Number Reporting Use Daily or Most Days8-weekshow often product (e-cigarette or patch) was used (everyday except while hospitalized, most days, a few times a week, once a week, less than once a week, not at all) Result reported is those that used the product daily or most days
Spirometry - FEV1day of surgery and 8-weekschange in FEV1 (mL) compared to baseline
Cotinine Level (Change in)day of surgery and 8-weekssalivary
Number of Participants With Postoperative Complications (Composite)30-days postopby chart review - research assistant or investigator examined notes and investigations postoperatively for complications by telephone self-report - patients were asked open-ended question about whether they experienced any postoperative complications
Long-term Smoking Status - Use of Conventional Cigarettes6 monthsby self-report (7-day point prevalence)
Number of Participants With Adverse Events as a Measure of Safety and Tolerability8 weeksall patients will be asked about adverse events each time they are contacted (day of surgery, 30-days postoperatively, and 8-weeks after randomization), and they will also be able to call to report adverse events to the study team any time during the study.
Number of Participants Postoperative Complications (Composite)30-days postopby telephone self-report
Spirometry - FEV1/FVC Changeday of surgery and 8-weeksChange in FEV1/FVC from baseline to day of surgery / 8-weeks. FEV1/FVC is expressed in percent. For example, if FEV1/FVC was 75%, 80%, and 85% at baseline, day of surgery and 8-weeks, result is reported as change in FEV1/FVC being +5% and +10% for day of surgery and 8-weeks respectively.

Countries

United States

Participant flow

Participants by arm

ArmCount
Nicotine Replacement Therapy (NRT)
As described above
10
Electronic Cigarette (END)
As described above
20
Total30

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up11

Baseline characteristics

CharacteristicNicotine Replacement Therapy (NRT)Electronic Cigarette (END)Total
Age, Continuous53 years
STANDARD_DEVIATION 10.6
54 years
STANDARD_DEVIATION 12.7
54 years
STANDARD_DEVIATION 12
Cigarettes smoked per day10.8 cigarettes
STANDARD_DEVIATION 6.6
15.3 cigarettes
STANDARD_DEVIATION 10.5
13.8 cigarettes
STANDARD_DEVIATION 9.2
COPD1 Participants6 Participants7 Participants
Day seen prior to surgery16.5 days
STANDARD_DEVIATION 9.5
11.2 days
STANDARD_DEVIATION 7.9
13.0 days
STANDARD_DEVIATION 8.4
Diabetes0 Participants2 Participants2 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants2 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants18 Participants28 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Exhaled CO (ppm)16.1 ppm
STANDARD_DEVIATION 7.7
21.7 ppm
STANDARD_DEVIATION 11.5
19.8 ppm
STANDARD_DEVIATION 10.2
Fagerstrom score2.5 units on a scale out of 10 min 1 max 10
STANDARD_DEVIATION 0.9
3.7 units on a scale out of 10 min 1 max 10
STANDARD_DEVIATION 2.6
3.3 units on a scale out of 10 min 1 max 10
STANDARD_DEVIATION 2
FEV1/FVC (%)105 percent
STANDARD_DEVIATION 81.3
68.2 percent
STANDARD_DEVIATION 13
80.5 percent
STANDARD_DEVIATION 35.8
FEV1 (L)3.14 L
STANDARD_DEVIATION 1.35
2.78 L
STANDARD_DEVIATION 1.11
2.9 L
STANDARD_DEVIATION 1.2
FVC (L)3.52 L
STANDARD_DEVIATION 1.28
4.03 L
STANDARD_DEVIATION 1.32
3.9 L
STANDARD_DEVIATION 1.31
Heart disease0 Participants1 Participants1 Participants
Hypertension3 Participants7 Participants10 Participants
Number of years smoking32 years
STANDARD_DEVIATION 16.4
32 years
STANDARD_DEVIATION 15.6
32 years
STANDARD_DEVIATION 15.9
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Black or African American
3 Participants5 Participants8 Participants
Race (NIH/OMB)
More than one race
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants3 Participants3 Participants
Race (NIH/OMB)
White
5 Participants11 Participants16 Participants
Salivary cotinine (ng/ml)130.1 ng/ml
STANDARD_DEVIATION 75.3
209.6 ng/ml
STANDARD_DEVIATION 110.3
183.1 ng/ml
STANDARD_DEVIATION 98.6
Sex: Female, Male
Female
1 Participants2 Participants3 Participants
Sex: Female, Male
Male
9 Participants18 Participants27 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 20
other
Total, other adverse events
6 / 1010 / 20
serious
Total, serious adverse events
0 / 100 / 20

Outcome results

Primary

Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)

Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide \<10ppm. Time Frame depends on date of preadmission clinic visit

Time frame: day of surgery (expected average around 1-2 weeks after enrollment/randomization)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)2 Participants
Electronic Cigarette (END)Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)3 Participants
Secondary

Cotinine Level (Change in)

salivary

Time frame: day of surgery and 8-weeks

ArmMeasureGroupValue (MEAN)Dispersion
Nicotine Replacement Therapy (NRT)Cotinine Level (Change in)day of surgery106 ng/mlStandard Deviation 137
Nicotine Replacement Therapy (NRT)Cotinine Level (Change in)8-weeks34 ng/mlStandard Deviation 89
Electronic Cigarette (END)Cotinine Level (Change in)day of surgery19 ng/mlStandard Deviation 119
Electronic Cigarette (END)Cotinine Level (Change in)8-weeks-48 ng/mlStandard Deviation 103
Secondary

Frequency of Use of Product - Number Reporting Use Daily or Most Days

how often product (e-cigarette or patch) was used (everyday except while hospitalized, most days, a few times a week, once a week, less than once a week, not at all) Result reported is those that used the product daily or most days

Time frame: 8-weeks

Population: in-person visit at 8-weeks, or make-up phone call if unavailable in-person

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Frequency of Use of Product - Number Reporting Use Daily or Most Days6 Participants
Electronic Cigarette (END)Frequency of Use of Product - Number Reporting Use Daily or Most Days16 Participants
Secondary

How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others

7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree

Time frame: 8-weeks

ArmMeasureValue (MEDIAN)
Nicotine Replacement Therapy (NRT)How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others7 units on a scale out of 7
Electronic Cigarette (END)How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others6 units on a scale out of 7
Secondary

How Satisfied the Patient Was With the Product (E-cigarette or Patch)

7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree

Time frame: 8-weeks

ArmMeasureValue (MEDIAN)
Nicotine Replacement Therapy (NRT)How Satisfied the Patient Was With the Product (E-cigarette or Patch)5 units on a scale out of 7
Electronic Cigarette (END)How Satisfied the Patient Was With the Product (E-cigarette or Patch)5.5 units on a scale out of 7
Secondary

Long-term Smoking Status - Use of Conventional Cigarettes

by self-report (7-day point prevalence)

Time frame: 6 months

Population: those lost assumed to still be smoking

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Long-term Smoking Status - Use of Conventional Cigarettes1 Participants
Electronic Cigarette (END)Long-term Smoking Status - Use of Conventional Cigarettes5 Participants
Secondary

Number of Participants Postoperative Complications (Composite)

by telephone self-report

Time frame: 30-days postop

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Number of Participants Postoperative Complications (Composite)2 Participants
Electronic Cigarette (END)Number of Participants Postoperative Complications (Composite)5 Participants
Secondary

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

all patients will be asked about adverse events each time they are contacted (day of surgery, 30-days postoperatively, and 8-weeks after randomization), and they will also be able to call to report adverse events to the study team any time during the study.

Time frame: 8 weeks

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Number of Participants With Adverse Events as a Measure of Safety and Tolerabilityany adverse event3 Participants
Nicotine Replacement Therapy (NRT)Number of Participants With Adverse Events as a Measure of Safety and Tolerabilitymoderate adverse event (required intervention)1 Participants
Electronic Cigarette (END)Number of Participants With Adverse Events as a Measure of Safety and Tolerabilityany adverse event10 Participants
Electronic Cigarette (END)Number of Participants With Adverse Events as a Measure of Safety and Tolerabilitymoderate adverse event (required intervention)1 Participants
Secondary

Number of Participants With Dual Use

use of both regular and e-cigarettes concurrently

Time frame: on day of surgery and 8-weeks after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Number of Participants With Dual Use3 Participants
Electronic Cigarette (END)Number of Participants With Dual Use2 Participants
Secondary

Number of Participants With Postoperative Complications (Composite)

by chart review - research assistant or investigator examined notes and investigations postoperatively for complications by telephone self-report - patients were asked open-ended question about whether they experienced any postoperative complications

Time frame: 30-days postop

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Number of Participants With Postoperative Complications (Composite)by chart review6 Participants
Nicotine Replacement Therapy (NRT)Number of Participants With Postoperative Complications (Composite)by telephone self-report2 Participants
Electronic Cigarette (END)Number of Participants With Postoperative Complications (Composite)by chart review5 Participants
Electronic Cigarette (END)Number of Participants With Postoperative Complications (Composite)by telephone self-report5 Participants
Secondary

Report of How Helpful the Product Was for Quitting

7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree

Time frame: 8-weeks

ArmMeasureValue (MEDIAN)
Nicotine Replacement Therapy (NRT)Report of How Helpful the Product Was for Quitting5 units on a scale out of 7
Electronic Cigarette (END)Report of How Helpful the Product Was for Quitting6 units on a scale out of 7
Secondary

Smoking Reduction

50% or less regular cigarette use compared to baseline as determined by asking participants to self-report daily cigarette use in cigarettes per day at each time point.

Time frame: on day of surgery and 8-weeks after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Smoking Reduction7 Participants
Electronic Cigarette (END)Smoking Reduction13 Participants
Secondary

Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)

by self-report and confirmed by exhaled CO\<10ppm - confirmed abstinent

Time frame: 8-weeks

Population: Those lost to follow-up assumed to still be smoking (1 in NRT group). Those who had telephone interview were unable to have exhaled CO verification (n=1 in NRT group, n=2 in END group). Since they were not verified by exhaled CO, they were not considered abstinent.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nicotine Replacement Therapy (NRT)Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)0 Participants
Electronic Cigarette (END)Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)3 Participants
Secondary

Spirometry - FEV1

change in FEV1 (mL) compared to baseline

Time frame: day of surgery and 8-weeks

ArmMeasureGroupValue (MEAN)Dispersion
Nicotine Replacement Therapy (NRT)Spirometry - FEV1change in FEV1 day of surgery-236 mLStandard Deviation 585
Nicotine Replacement Therapy (NRT)Spirometry - FEV1change in FEV1 8-weeks-300 mLStandard Deviation 497
Electronic Cigarette (END)Spirometry - FEV1change in FEV1 day of surgery-163 mLStandard Deviation 549
Electronic Cigarette (END)Spirometry - FEV1change in FEV1 8-weeks292 mLStandard Deviation 503
Secondary

Spirometry - FEV1/FVC Change

Change in FEV1/FVC from baseline to day of surgery / 8-weeks. FEV1/FVC is expressed in percent. For example, if FEV1/FVC was 75%, 80%, and 85% at baseline, day of surgery and 8-weeks, result is reported as change in FEV1/FVC being +5% and +10% for day of surgery and 8-weeks respectively.

Time frame: day of surgery and 8-weeks

ArmMeasureGroupValue (MEAN)Dispersion
Nicotine Replacement Therapy (NRT)Spirometry - FEV1/FVC ChangeFEV1/FVC on day of surgery compared to baseline-32.2 percent (change from baseline)Standard Deviation 74
Nicotine Replacement Therapy (NRT)Spirometry - FEV1/FVC ChangeFEV1/FVC at 8 weeks compared to baseline-38.1 percent (change from baseline)Standard Deviation 79.2
Electronic Cigarette (END)Spirometry - FEV1/FVC ChangeFEV1/FVC on day of surgery compared to baseline-1.6 percent (change from baseline)Standard Deviation 8.2
Electronic Cigarette (END)Spirometry - FEV1/FVC ChangeFEV1/FVC at 8 weeks compared to baseline2.0 percent (change from baseline)Standard Deviation 10.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026